Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03075696
Recruitment Status : Recruiting
First Posted : March 9, 2017
Last Update Posted : December 6, 2021
Information provided by (Responsible Party):
Hoffmann-La Roche